<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03691779</url>
  </required_header>
  <id_info>
    <org_study_id>VX18-445-106</org_study_id>
    <secondary_id>2018-001695-38</secondary_id>
    <nct_id>NCT03691779</nct_id>
  </id_info>
  <brief_title>Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age</brief_title>
  <official_title>A Phase 3 Study Evaluating the Pharmacokinetics, Safety, and Tolerability of VX-445/TEZ/IVA Triple Combination Therapy in Cystic Fibrosis Subjects 6 Through 11 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the pharmacokinetics (PK), safety, tolerability, efficacy, and
      pharmacodynamic effect of VX-445, tezacaftor (TEZ), and ivacaftor (IVA) when dosed in triple
      combination (TC) in Cystic Fibrosis (CF) subjects 6 through 11 years of age with F/F and F/MF
      genotypes.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 2, 2018</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Observed pre-dose concentration (Ctrough) of VX-445, TEZ, and IVA</measure>
    <time_frame>Day 1 through 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Maximum Observed Concentration (Cmax) of VX-445, TEZ, and IVA</measure>
    <time_frame>Day 1 through 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Area under the concentration versus time curve during a dosing interval (AUCtau) of VX-445, TEZ, and IVA</measure>
    <time_frame>Day 1 through 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Safety and tolerability as assessed by number of subjects with adverse events and serious adverse events</measure>
    <time_frame>from baseline through safety follow-up (28 Weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A: Maximum observed concentration (Cmax) of VX-445, TEZ, and IVA metabolites</measure>
    <time_frame>from Day 1 through 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Observed pre-dose concentration (Ctrough) of VX-445, TEZ, and IVA metabolites</measure>
    <time_frame>from Day 1 through 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Area under the concentration versus time curve during a dosing interval (AUCtau) of VX-445, TEZ, and IVA metabolites</measure>
    <time_frame>from Day 1 through 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Safety and tolerability as assessed by number of subjects with adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>from baseline through safety follow-up (28 Weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Absolute change in percent predicted forced expiratory volume in 1 second (ppFEV1)</measure>
    <time_frame>from baseline through Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Absolute change in sweat chloride</measure>
    <time_frame>from baseline through Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Absolute change in Cystic Fibrosis Questionnaire Revised (CFQ R) respiratory domain score</measure>
    <time_frame>from baseline through Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Absolute change in body mass index (BMI) and BMI for age-z-score</measure>
    <time_frame>from baseline at Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Absolute change in weight and weight for age-z-score</measure>
    <time_frame>from baseline at Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Absolute change in height and height for age-z-score</measure>
    <time_frame>from baseline at Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Absolute change in the Modified Facial Hedonic Scale</measure>
    <time_frame>from baseline at Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts B: Ctrough of VX-445, TEZ, IVA, and IVA metabolites</measure>
    <time_frame>Day 1 through Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Absolute change in lung clearance index2.5 (LCI2.5)</measure>
    <time_frame>from baseline through Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Number of Pulmonary Exacerbations (PEx)</measure>
    <time_frame>from baseline through Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Number of CF Related Hospitalizations</measure>
    <time_frame>from baseline through Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Part A: Triple Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 100 mg VX-445/ 50 mg TEZ/ 75 mg IVA as an FDC tablet in the morning and 75 mg IVA as mono tablet in the evening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Triple Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive VX-445/TEZ/IVA as FDC tablet in the morning and IVA as mono tablet in the evening with the dose to be based on the outcome of Part A.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-445</intervention_name>
    <description>Fixed dose combination (FDC) tablet (VX-445/TEZ/IVA)</description>
    <arm_group_label>Part A: Triple Combination</arm_group_label>
    <arm_group_label>Part B: Triple Combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TEZ</intervention_name>
    <description>FDC tablet (VX-445/TEZ/IVA)</description>
    <arm_group_label>Part A: Triple Combination</arm_group_label>
    <arm_group_label>Part B: Triple Combination</arm_group_label>
    <other_name>tezacaftor; VX-661</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IVA</intervention_name>
    <description>FDC tablet (VX-445/TEZ/IVA) and IVA mono tablet</description>
    <arm_group_label>Part A: Triple Combination</arm_group_label>
    <arm_group_label>Part B: Triple Combination</arm_group_label>
    <other_name>ivacaftor; VX-770</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Homozygous or heterozygous for F508del mutation (F/F or F/MF genotypes)

          -  Forced expiratory volume in 1 second (FEV1) value â‰¥40% of predicted mean for age, sex,
             and height.

        Key Exclusion Criteria:

          -  Clinically significant cirrhosis with or without portal hypertension

          -  Lung infection with organisms associated with a more rapid decline in pulmonary
             status.

          -  Solid organ or hematological transplantation.

        Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Respiratory and Critical Care Specialists, P.A., Children's Hospitals and Clinics of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwell Health- Long Island Jewish Medical Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queensland Children's Hospital</name>
      <address>
        <city>South Brisbane</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital at Westmead</name>
      <address>
        <city>Westmead</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Health Ireland at Crumlin</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Health Ireland at Temple Street</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Children's Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brompton &amp; Harefield NHS Foundation Trust, Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Ireland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 28, 2018</study_first_submitted>
  <study_first_submitted_qc>September 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2018</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivacaftor</mesh_term>
    <mesh_term>VX-445</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

